Open Nav

Poxel SA

  • Noah Beerman, Poxel SA

Increase Investor Visibility

  • Date:Wednesday, October 17
  • Time:9:00 AM - 9:15 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Poxel uses its development expertise in metabolism to advance drug candidates focused on the treatment of metabolic disorders, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Imeglimin Phase 3 program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. DRX-065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC), is in Phase 1 and being developed for NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases.
  • Company
  • Company HQ City:Lyon
  • Company HQ Country:France
  • Market Cap:~$200M
  • Ticker:POXEL PA
  • Exchange:Euronext France
  • CEO/Top Company Official:Thomas Kuhn
  • Year Founded:2009
  • Main Therapeutic Focus:Metabolic Diseases
  • Lead Product in Development :Imeglimin
  • Development Phase of Primary Product:Phase III
Noah Beerman
Poxel SA